Puma Biotechnology Reports Third Quarter 2013 Financial Results

Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2013.

Unless otherwise stated, all comparisons are for the third quarter and nine months ended September 30, 2013, compared to the third quarter and nine months ended September 30, 2012.

Based on accounting principles generally accepted in the United States (GAAP), Puma reported a net loss applicable to common stock of $14.3 million, or $0.50 per share, for the third quarter of 2013, compared to a net loss of $25.9 million, or $1.29 per share, for the third quarter of 2012. Net loss applicable to common stock for the nine months ended September 30, 2013, was $38.7 million, or $1.35 per share, compared to $52.4 million, or $2.62 per share, for the nine months ended September 30, 2012.

Adjusted net loss applicable to common stock was $12.3 million, or $0.43 per share, for the third quarter of 2013, compared to adjusted net loss applicable to common stock of $3.6 million, or $0.18 per share, for the third quarter of 2012. Adjusted net loss applicable to common stock for the nine months ended September 30, 2013, was $33.6 million, or $1.17 per share, compared to $11.5 million, or $0.58 per share, for the nine months ended September 30, 2012. Adjusted net loss applicable to common stock excludes stock-based compensation expense and external costs associated with ongoing clinical trials of our lead product candidate, PB272 (neratinib (oral)), that Puma assumed from a licensor and which it refers to as licensor legacy clinical trials. For a reconciliation of adjusted net loss applicable to common stock to reported net loss applicable to common stock, please see the financial tables at the end of this news release.

Net cash used in operating activities for the third quarter of 2013 was $12.0 million. Net cash used in operating activities for the nine months ended September 30, 2013, was $41.4 million. At September 30, 2013, Puma had cash and cash equivalents of $51.3 million and marketable securities of $44.4 million, compared to $137.4 million of cash and cash equivalents at December 31, 2012. As previously noted, Puma’s license agreement for PB272 established a limit on the Company’s expenses related to certain clinical trials Puma assumed from the licensor, or legacy clinical trials. Puma reached this limit, or cap, during the fourth quarter of 2012; therefore, the licensor is responsible for expenses related to the legacy clinical trials until such trials are completed. The license agreement requires the Company to bill the licensor quarterly for external “out-of-pocket” costs in excess of the cap cost. At September 30, 2013, the Company reported a receivable of approximately $11.3 million associated with outstanding invoices to the licensor. The Company anticipates receiving payments for these outstanding invoices by the end of 2013.

If you liked this article you might like

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

5 New Breast Cancer Treatments That Are Helping to Save Lives

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)